

### Remarks

The foregoing amendments are made to insert and/or correct required SEQ ID NO: identifiers associated with various listed sequences. Accordingly, Applicants respectfully request entry of the sequence listing submitted herewith under 37 C.F.R. §§ 1.821-1.825, which submission contains no new matter.

Additionally, two obvious typographical errors regarding the 3-letter code for tyrosine (i.e., "Tyr" replacing "Try" as filed) are corrected in paragraphs [0034] and [0050], identification and correction of which would immediately be obvious to one of ordinary skill in the art in view of the specification as filed, support for which may be found at, e.g., page 17, line 27; page 21, line 27; page 22, line 35; page 23, line 32. No new matter is added by the present amendments.


Applicants respectfully request that the present amendments be entered prior to examination of the instant application. After entry of the amendments provided herewith, Claims 1-19 will be pending and under active consideration.

Applicants believe that the present application is now in conditions for allowance which is respectfully requested. The Examiner is encouraged to call the undersigned to discuss any issues related to the prosecution of the instant application.

No fees are believed due for this submission. However, if a fee is due, the Commissioner is hereby authorized to charge payment of any fees associated with this communication to Applicant's Deposit Account No. 010535. Additionally, the Commissioner is hereby authorized to charge payment or credit overpayment of any fees during the pendency of this application to Applicant's Deposit Account No. 010535.

Respectfully submitted,  
AMYLIN PHARMACEUTICALS, INC.

Dated: June 19, 2008

By:   
Steven C. Koerber  
Registration No. 54,233

CUSTOMER NUMBER 044638  
AMYLIN PHARMACEUTICALS, INC.  
9360 Towne Centre Drive  
San Diego, CA 92121  
Telephone: 858.552.2200  
Facsimile: 858.552.1936